Introduction {#sec1-1}
============

Pancreatic fluid collections (PFCs) can be categorized as acute peripancreatic fluid collections, pancreatic pseudocysts, acute necrotic collections, and walled-off pancreatic necrosis (WOPN). Symptomatic PFCs can be treated surgically, percutaneously, or endoscopically \[[@ref1],[@ref2]\]. Though surgery and percutaneous treatment are more traditional forms of management of PFCs, both modalities have their drawbacks. Surgery is associated with higher rates of morbidity (5-35%) and mortality (6%), whereas the external catheter in percutaneous treatment increases the risk of infection or fistula formation (14%) \[[@ref3],[@ref4]\]. The endoscopic management of peripancreatic fluid collections has also been technically challenging and associated with significant shortcomings, however the recent development of the lumen-apposing self-expandable metallic stent (LASEMS) attempts to overcome the limitations of current endoscopic accessories used in the treatment of PFCs \[[@ref5]\].

Traditional endoscopic management of PFCs has included the use of a variety of accessories. Plastic stents were conventionally used for drainage, and although the pigtail feature of the plastic stents prevents migration, their narrow lumen may cause premature occlusion in up to 18% of cases, resulting in frequent stent exchanges or placement of additional stents \[[@ref21],[@ref22]\]. After the development of plastic stents, fully covered, self-expanding metal stents offered a larger diameter lumen for more efficient drainage and less likelihood of stent occlusion. However, these stents were tubular and could migrate, resulting in inefficient drainage, leakage, and a more frequent need for retrieval and replacement of the stent if it migrated. Currently, it is very difficult to predict which WOPN collections can be efficiently and safely managed without necrosectomy. In large PFCs with considerable necrosis, necrosectomy is usually required and is commonly performed when the initial endoscopic drainage has not been effective \[[@ref6],[@ref7]\].

The AXIOS lumen-apposing stent (Xlumena Inc., Mountain View, California, USA) attempts to overcome the limitations of current endoscopic accessories with a removable fully covered, nitinol, braided stent deployed under endoscopic ultrasound (EUS) guidance. A "dumbbell" configuration with two large flanges aims to avoid stent migration. When fully expanded the stent has a flange diameter twice that of the "saddle" section allowing apposition of the tissue layers. The large diameter capacity of the stent also allows necrosectomy in repeated sessions without the need for stent replacement \[[@ref8],[@ref9]\]. The stent is available in two diameter sizes, 10 or 15 mm.

A few authors have recently summarized the clinical and technical success of using the LASEMS in PFC drainage. In the present review, the indications, techniques, success rates, limitations, and complications reported thus far with EUS-guided PFC drainage using the LASEMS are described.

Materials and methods {#sec1-2}
=====================

An extensive English language literature search was conducted using PubMed, Medline, and Google to identify peer-reviewed original and review articles using the keywords 'endoscopic ultrasound', 'lumen-apposing self-expandable metal stent', 'pancreatic fluid collection', 'AXIOS' and 'drainage'. Only human articles were selected. The references of pertinent studies were manually searched to identify additional relevant studies. The indications, procedural details, technical and clinical success rates, complications, and limitations were considered as part of the inclusion criteria. Search results yielded mostly small sample sized prospective studies and case reports, which limited statistical analysis in the form of meta-analysis. None of the authors have any conflicts of interest or financial relationships with the company that produces or distributes the device described in the review article.

Results {#sec1-3}
=======

Eleven original articles published were considered appropriate to be included in the review article. Of these, five were case reports from Italy \[[@ref10],[@ref14]\], New York, USA \[[@ref17],[@ref19]\], and Spain \[[@ref11]\]. Six articles were case series from Italy \[[@ref13]\], Colorado, USA \[[@ref15]\], Netherlands \[[@ref12]\], Spain \[[@ref18]\], Utah, USA \[[@ref20]\] and Japan \[[@ref9]\]. All studies have been summarized in Table(s) [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}.

###### 

Patient characteristics in lumen-apposing self-expandable metallic stent cases
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Summary of procedure and outcomes describing endoscopic ultrasound-guided pancreatic fluid collection drainage with lumen-apposing self-expandable metallic stent cases
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Demographics {#sec2-1}
------------

As mentioned in [Table 1](#T1){ref-type="table"}, most of the cases were reported from European countries. A total of 298 patients were included across all studies. 99 patients were female while 199 were male. Mean age calculated from all reported cases was 56 years.

Indications {#sec2-2}
-----------

Indications for EUS-guided pancreatic fluid drainage included the following symptomatic lesions: pancreatic pseudocyst, walled off pancreatic necrosis, infected pancreatic necrosis, and acute peripancreatic fluid collection. All patients who underwent EUS-guided placement of LASEMS were symptomatic at the time of diagnosis. PFC diameter ranged from 50 to 200 mm.

Technique {#sec2-3}
---------

An oblique/forward-viewing therapeutic linear array echoendoscope was used in all cases. A transgastric approach via the antral wall was performed in 259/298 (87%) patients while a transduodenal approach was performed in 22/298 (7%) cases. A rarer transesophageal approach was only used in two patients across all studies. The remaining 15 patients were not included in the transgastric, transduodenal, or transesophageal approach because the authors did not describe a specific approach in the study. A 0.035-inch guidewire was passed and the tract dilated by using of one of the following: dilating bougie, dilating balloon, NAVIX device, cystosome, or electrocautery catheter. The NAVIX device (Xlumena Inc., Mountain View, California, USA)is a multi-function system that enables exchange-free access, tract dilation and delivery of two guidewires during endoscopic pancreatic pseudocyst drainage \[[@ref10]\]. The LASEMS was inserted under direct fluoroscopic and EUS control. Most endoscopists prefer performing the procedure with added radiographic imaging that allows for more efficient stent insertion, however the procedure can be performed without fluoroscopic guidance. In most cases, the selection of a 10-mm or 15-mm stent diameter was based on the contents of the PFC and the presence of solid debris identified on EUS. A larger 15-mm diameter was preferred for PFCs containing solids or necrotic material in order to allow for subsequent debridement, irrigation, and cystoscopy. The AXIOS stent was used in 100% of patients who underwent placement of LASEMS. Two patients underwent stent placement with the novel Hot-AXIOS stent delivery system. The Hot AXIOS System (Xlumena Inc., Mountain View, California, USA)combines a cautery-enabled access catheter with the therapeutic AXIOS Stent for a streamlined, exchange-free procedure \[[@ref11]-[@ref14]\]. It is important to note that Hot-AXIOS is not available in the United States at this time but is used in Europe.

Technical and clinical success rate {#sec2-4}
-----------------------------------

The combined clinical success rate was 96% in all case reports and case series with most studies measuring success as clinical improvement and alleviation of pain symptoms. The combined technical success rate was 97% across all studies. Technical success was measured as complete drainage of the PFC. Studies that reported lower technical success rates were Gornals *et al* 2013 \[[@ref16]\] and Shah *et al* \[[@ref15]\]. In Gornals *et al* 2013 \[[@ref16]\], the stent was successfully positioned in all patients except one, due to a failure of the delivery system. In this failure case, PFC drainage was completed by placing two plastic double-pigtail stents. The clinical success rate was 100% in that study however, and patients experienced immediate symptom relief after the interventions. In Shah *et* *al* \[[@ref15]\], the three unsuccessful LASEMS placements were possibly related to limited operator experience as well as one case of device malfunction. As stated in this study, it is likely that technical success increased based on operator experience. Finally, in Siddiqui *et al* \[[@ref20]\], the two cases of technical failure were due to stent maldeployment in the pancreatic pseudocyst group.

Complications and adverse outcomes {#sec2-5}
----------------------------------

Four studies had no early adverse outcomes. Minor early complications were reported in seven studies and are summarized in [Table 2](#T2){ref-type="table"}. The AXIOS stent, with its "dumbbell" configuration and two large flanges, aims to avoid stent migration. In our review, Rinninella, Shah and Itoi each reported only one case of stent migration, totaling three cases of stent migration in all \[[@ref9],[@ref13],[@ref15]\]. Rinninella *et al* reported major complications of massive bleeding and perforation in two patients \[[@ref13]\]. Gornals *et al* 2011 reported two cases of pneumothorax that were both presumably caused by a trans-esophageal approach to LASEMS placement \[[@ref11]\]. Other early complications reported included pneumoperitoneum, access-site infection, self-limited oozing, abdominal pain, back pain, and PFC infection. There were no mortalities directly related to the procedure.

Follow up and stent removal {#sec2-6}
---------------------------

In 8 of 11 studies, there were no complications during removal of the LASEMS. The majority of stents were removed using a snare or rat-tooth forceps. In Walter *et al*, endoscopic stent removal was performed in 47 of 57 patients (82%). In the 10 patients in whom endoscopic stent removal was not performed, the reasons included: migration of the stent, stent dislodgement during necrosectomy, removal during surgery, and refusal by the patient \[[@ref12]\]. In Fabbri *et al*, attempts at removal of the LASEMS showed the stent embedded in the gastric wall. It was removed using rat-tooth forceps \[[@ref14]\]. This case represented a late complication of LASEMS placement and was the first case describing the "buried stent". Though the majority of AXIOS stents were removed in the studies included in our review, there is little data regarding recurrence after removal or outcomes for stents left in permanently. In Siddiqui *et al* follow up of patients after LASEMS removal was 9 months for the walled-off pancreatic necrosis group \[[@ref20]\]. Of the 68 patients, there was 1 recurrence that occurred 4 months after removal of the AXIOS stent that was retreated successfully by placement of a new stent through the previous cyst-gastrostomy tract \[[@ref20]\]. As more prospective studies following patients long-term after AXIOS stent insertion and removal are reported, more data will be available regarding the pros and cons of stent removal versus permanent stent insertion.

Limitations {#sec2-7}
-----------

Thus far, clinically successful cases have been published with few complications reported, but this may be due to a publication bias as the procedure is fairly new. As more cases that are technically and clinically relevant are published, further data may be assessed regarding the potential efficacy and safety of LASEMS in the treatment of PFCs.

Summary and future directions {#sec2-8}
-----------------------------

Our current literature review suggests that LASEMS is an innovative therapeutic approach for PFC drainage with excellent efficacy, safety, and relatively few adverse outcomes. Conventionally, multiple plastic stents are placed to drain PFCs. However, the migration rates, smaller diameter, and the need for multiple stent placements has necessitated alternative options such as placing metal stents to permit efficient drainage. Because of the "dumbbell" shape of the LASEMS and its large diameter, apposition and a reduced risk of migration are possible. A distinct advantage of the anchoring design and large lumen diameter of this device is the ability to perform direct endoscopic necrosectomy through the stent while maintaining stent integrity, especially if the 15-mm diameter stent is used. The large diameter enables endoscope advancement into the PFC for debris removal while the flanges keep the stent in place \[[@ref15]-[@ref19]\]. LASEMS placement for PFC drainage showed a technical success rate as defined by PFC resolution of 97%. It is likely that technical success will increase with additional experience and use. Clinical success was measured at 96% across all studies.

This is the first review article reporting clinical and technical results of the LASEMS stent selectively designed for PFC drainage. It shows that the LASEMS may be, in the future, a feasible and safe alternative to surgery or percutaneous drainage in patients with PFCs. In the cases described in the literature, the majority of patients progressed adequately in a short period of time without significant complications related to the procedure. Preliminary reports appear promising and large multicenter prospective studies are needed in the future to further determine its safety and efficacy. With further experience and the development of more sophisticated accessories, the arena of EUS-guided drainage and stent placement is likely to expand. In conclusion, our study showed that the LASEMS is safe and efficient for PFC drainage. Advantages of LASEMS compared with other stents include single-step deployment and the ability to perform direct endoscopic debridement with minimal stent migration. Whether the safety and efficacy of LASEMS is superior to conventional double-pigtail plastic stents for PFC drainage would require a prospective, randomized, controlled trial.
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